Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

mRNA company Moderna Inc. (NASDAQ:MRNA) said Elizabeth Nabel has resigned from its board to avoid any potential or apparent conflict of interest. She is president of Brigham and Women’s Hospital, a site enrolling patients in the Phase III trial of Moderna’s COVID-19 vaccine, mRNA-1273. Nabel is also a professor of medicine at Harvard Medical School.

San Raffaele Telethon Institute for Gene Therapy spinout Genespire Inc. named Jörn Aldag chairman. He is CEO of Hookipa Pharma Inc. (NASDAQ:HOOK) and was CEO of uniQure N.V. (NASDAQ:QURE). Genespire raised €16 million ($17.4 million) in an April series A round from Sofinnova Partners (see “Expanding Italy’s Ecosystem”)...